for those participating in CKD trials, mean BMI 35.435.7 kg/m 2 versus 31.2 kg/m 2 in those not on GLP-1 RAs)
[1] Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations
The alpha cells in the pancreas secrete proglucagon when blood glucose levels are low
For researchers seeking personalised product recommendations tailored to their specific objectives, please email our support team at [email protected]
Short needles, fine gauges, low dead space, and unit markings that make small-volume dose measurement precise
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease